EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease

Partow Kebriaei, Jack Hayes, Andrew Daly, Joseph Uberti, David I Marks, Robert Soiffer, Edmund K Waller, Elizabeth Burke, Donna Skerrett, Elizabeth Shpall, Paul J Martin

Biology of Blood and Marrow Transplantation · 2020-05 · 26 (5) · 835-844

DOI: 10.1016/j.bbmt.2019.08.029 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Biology of Blood and Marrow Transplantation, 2020-05. Verfasst von Partow Kebriaei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: pkebriae@mdanderson.…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Osiris Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationMesenchymal Stem Cell TransplantationMesenchymal Stem CellsAcute DiseaseAdultChildHumansSteroids

Stichwörter der Autor:innen

Acute graft-versus-host diseaseAllogeneicHematopoietic cell transplantationMesenchymal stem cellsSteroid

Substanzen

Steroids

Autor:innen und Institutionen

  • Department of Stem Cell and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: pkebriae@mdanderson.org.
  • Mesoblast, New York, New York.
  • Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.
  • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
  • University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
  • Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Förderung

  • NCI NIH HHS
  • Osiris Therapeutics

Zitieren

APA

Kebriaei, P., Hayes, J., Daly, A., Uberti, J., Marks, D. I., Soiffer, R., Waller, E. K., Burke, E., Skerrett, D., Shpall, E., & Martin, P. J. (2020). A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 26(5), 835-844. https://doi.org/10.1016/j.bbmt.2019.08.029

Vancouver

Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 2020;26(5):835-844. doi:10.1016/j.bbmt.2019.08.029

BibTeX
@article{Kebriaei2020,
  author = {Kebriaei, Partow and Hayes, Jack and Daly, Andrew and Uberti, Joseph and Marks, David I and Soiffer, Robert and Waller, Edmund K and Burke, Elizabeth and Skerrett, Donna and Shpall, Elizabeth and Martin, Paul J},
  title = {A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease},
  journal = {Biology of Blood and Marrow Transplantation},
  year = {2020},
  volume = {26},
  number = {5},
  pages = {835--844},
  doi = {10.1016/j.bbmt.2019.08.029}
}
Kostenlos starten →